Nanomedicine Research

At Houston Methodist, our goal is to bring nanotechnologies to the clinic. By using interdisciplinary methods to combine nanoengineering, mathematical modeling and biomedical sciences, we develop nanotechnology-enabled therapeutic and diagnostic platforms to combat diseases including cancer, diabetes, cardiovascular and infectious diseases. Our main strategies are to make it possible for clinicians to detect disease early from blood proteomic signatures through the use of nanochips, to produce injectable nanovectors for targeted therapies and to design and create intelligent implants that allow controlled, time-released doses of substances. We have also created nanoscale scaffolding to aid in bone tissue engineering. Through our research, we are also attempting to understand the physics of mass transport within a cancer lesion and mass exchanges between cancer and surrounding host biology in order to create better nanomedicine treatments for cancer. We use several core facilities to advance our research goals; Molecular Diagnostics, Nanoengineering and Peptidomics-Nanoengineering to name just a few.

SCIENTISTS CREATE NANODEVICE TO DELIVER IMMUNOTHERAPY WITHOUT SIDE EFFECTS

Nanodevice for immunotherapy

Houston Methodist scientists led by Alessandro Grattoni, PhD, have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer. Learn More>

George and Angelina Kostas Research Center for Cardiovascular Nanomedicine Annual Meeting

Kostas Annual Meeting

The George and Angelina Kostas Research Center for Cardiovascular Nanomedicine Annual International Meeting will be held Nov. 13, 2019. Learn more> 


Houston Methodist research team receives nearly $4 million to test a transcutaneously refillable implant that administers pre-exposure prophylaxis drugs to subjects at risk of HIV-exposure. Learn more. 
Read More >

V-chip - device about the size of a business card can test for insulin, cholesterol, blood proteins, and even signs of viral or bacterial infection at the same time—with one drop of blood. Preliminary results were published by Nature Communications. Learn More. 
Read More >


Live Chat Available